Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Pasadena, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Reseda, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Reseda, CA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Sacramento, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Sunnyvale, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Torrance, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Ventura, CA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Ventura, CA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Aurora, CO
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Manchester, CT
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Manchester, CT
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Gainesville, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Naples, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Port Charlotte, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Sunrise, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Sunrise, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Tampa, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Tampa, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Weston, FL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Weston, FL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Atlanta, GA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Chicago, IL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Chicago, IL
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Des Moines, IA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Des Moines, IA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Kansas City, KA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Baltimore, MD
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Elkridge, MD
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Elkridge, MD
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Boston, MA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Bingham Farms, MI
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Bingham Farms, MI
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Golden Valley, MN
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Albany, NY
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Commack, NY
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Commack, NY
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
New York, NY
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
New York, NY
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
New York, NY
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Greensboro, NC
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Raleigh, NC
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Cleveland, OH
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Toledo, OH
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Tulsa, OK
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Hershey, PA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Dallas, TX
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Houston, TX
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Houston, TX
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Roanoke, VA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Kirkland, WA
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Kirkland, WA
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Morgantown, WV
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
mi
from
Innsbruck,
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
mi
from
Innsbruck,
Click here to add this to my saved trials
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated:  10/6/2017
mi
from
West Bloomfield Township, MI
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Status: Enrolling
Updated: 10/6/2017
mi
from
West Bloomfield Township, MI
Click here to add this to my saved trials